None
DE
Annexon Biosciences: Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
['Globenewswire', 'Europe']
FinanzNachrichten.de: News
Second Quarter 2026 Financial ResultsCash and operating runway: Cash, cash equivalents and short-term investments were $209.2 million as of June 30, 2026.
General and administrative (G&A) expenses: G&A expenses were $10.6 million for the quarter ended June 30, 2026, compared to $7.6 million for the quarter ended June 30, 2025.
The change in G&A expenses reflects ongoing corporate consulting and professional services costs for the advancement of our registrational programs.
G&A expenses were $10.6 million for the quarter ended June 30, 2026, compared to $7.6 million for the quarter ended June 30, 2025.
The change in G&A expenses reflects ongoing corporate consulting and professional services costs for the advancement of our registrational programs.